BCDA vs. AWH, FBRX, TXMD, KALA, JAN, CARA, LGVN, IBIO, APM, and ALTS
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Aspira Women's Health (AWH), Forte Biosciences (FBRX), TherapeuticsMD (TXMD), KALA BIO (KALA), JanOne (JAN), Cara Therapeutics (CARA), Longeveron (LGVN), iBio (IBIO), Aptorum Group (APM), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry.
Aspira Women's Health (NASDAQ:AWH) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
Aspira Women's Health has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.
Aspira Women's Health received 1 more outperform votes than BioCardia when rated by MarketBeat users. However, 52.17% of users gave BioCardia an outperform vote while only 24.07% of users gave Aspira Women's Health an outperform vote.
In the previous week, BioCardia had 3 more articles in the media than Aspira Women's Health. MarketBeat recorded 4 mentions for BioCardia and 1 mentions for Aspira Women's Health. BioCardia's average media sentiment score of 1.24 beat Aspira Women's Health's score of 0.72 indicating that Aspira Women's Health is being referred to more favorably in the media.
Aspira Women's Health currently has a consensus price target of $4.45, suggesting a potential upside of 198.66%. BioCardia has a consensus price target of $4.00, suggesting a potential upside of 33.78%. Given BioCardia's higher possible upside, research analysts plainly believe Aspira Women's Health is more favorable than BioCardia.
12.2% of Aspira Women's Health shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 4.3% of Aspira Women's Health shares are owned by company insiders. Comparatively, 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aspira Women's Health has a net margin of -163.95% compared to Aspira Women's Health's net margin of -2,208.76%. BioCardia's return on equity of 0.00% beat Aspira Women's Health's return on equity.
BioCardia has lower revenue, but higher earnings than Aspira Women's Health. Aspira Women's Health is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Summary
Aspira Women's Health beats BioCardia on 9 of the 16 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
